RELATED PARTY TRANSACTIONS (Details Textual) $ in Thousands |
3 Months Ended | 9 Months Ended |
|---|---|---|
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2026
USD ($)
|
|
| Related Party Transaction [Line Items] | ||
| Revenue sharing expense | $ 66 | $ 168 |
| Legal Fees | 67 | 67 |
| Oramed [Member] | ||
| Related Party Transaction [Line Items] | ||
| Legal Fees | 67 | 67 |
| Oramed [Member] | Related Party Financing Arrangements [Member] | ||
| Related Party Transaction [Line Items] | ||
| Convertible promissory notes | 4,400 | 4,400 |
| Oramed [Member] | Asset Acquisition Transaction [Member] | ||
| Related Party Transaction [Line Items] | ||
| Research and development expense associated with acquired in-process research and development assets | 4,900 | |
| Revenue sharing expense | 66 | 168 |
| Oramed [Member] | Clinical Trial Services Arrangements [Member] | ||
| Related Party Transaction [Line Items] | ||
| Research and development expense associated with acquired in-process research and development assets | 74 | 167 |
| Clinical trial services asset | 808 | 808 |
| Clinical trial management services amount | $ 492 | $ 1,114 |
| X | ||||||||||
- Definition Amount of clinical trial management services. No definition available.
|
| X | ||||||||||
- Definition Revenue sharing expense. No definition available.
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Includes, but is not limited to, software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|